Finance

Beta
Lists
ACE:STO
Ascelia Pharma AB
SEK 2.92
+1.39%
(+0.040) 1D
Jun 4, 9:15:33 AM GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for ACE...
Open
SEK 2.92
High
SEK 2.92
Low
SEK 2.88
Mkt. cap
389.27M
Avg. vol.
703.91K
Volume
16.27K
52-wk high
SEK 5.23
52-wk low
SEK 2.53
EPS
-SEK 0.59
Shares outstanding
133.54M
No. of employees
10
Open
SEK 2.92
High
SEK 2.92
Low
SEK 2.88
Mkt. cap
389.27M
Avg. vol.
703.91K
Volume
16.27K
52-wk high
SEK 5.23
52-wk low
SEK 2.53
EPS
-SEK 0.59
Shares outstanding
133.54M
No. of employees
10
News stories
From sources across the web
About Ascelia Pharma AB
CEOMagnus Corfitzen
Employees10
Founded1999
Headquarters-
SectorBiotechnology
Websiteascelia.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
18.66M
10.89M
11.61M
14.16M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.44M
4.31M
4.12M
3.19M
Operating expense
23.13M
15.25M
15.53M
17.17M
Total operating expenses
23.13M
15.25M
15.53M
17.17M
Operating income
-23.13M
-15.25M
-15.53M
-17.17M
Other non operating income
-2.00K
-
-218.00K
1.00K
EBT including unusual items
-23.20M
-15.72M
-15.93M
-17.03M
EBT excluding unusual items
-23.20M
-15.72M
-15.93M
-17.03M
Income tax expense
-218.00K
-50.00K
-67.00K
-648.00K
Effective tax rate
0.94%
0.32%
0.42%
3.81%
Other operating expenses
31.00K
57.00K
-194.00K
-174.00K
Net income
-22.98M
-15.67M
-15.86M
-16.38M
Net profit margin
-
-
-
-
Earnings per share
-0.20
-0.13
-0.13
-
Interest and investment income
1.84M
427.00K
3.47M
398.00K
Interest expense
-2.03M
-898.00K
-2.16M
-254.00K
Net interest expenses
-190.00K
-471.00K
1.31M
144.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-23.11M
-15.23M
-15.53M
-17.17M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer